Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Human leukocyte antigen A 02:01 TSC 200 - TScan Therapeutics

Next Previous
Drug Profile

Human leukocyte antigen A 02:01 TSC 200 - TScan Therapeutics

Alternative Names: HLA-A*02:01; HLA-A*02:01- TSC-200; TSC-200; TSC-200-A02; TSC-200-A0201; TSC-200-A2

Latest Information Update: 16 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TScan Therapeutics
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Anal cancer; Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Sarcoma
  • Discontinued Malignant melanoma; Ovarian cancer

Most Recent Events

  • 12 Nov 2025 TScan Therapeutics paused enrollment a phase I PLEXI trial in Solid tumours in the US due to focus on preclinical development of in vivo engineering to treat patients with solid tumors (NCT05973487)
  • 25 Sep 2025 Phase I development for non-small cell lungs cancer, Head and neck cancer, Cervical cancer and Anal cancer is ongoing in the US (Parenteral)
  • 25 Sep 2025 Discontinued - Phase-I for Malignant melanoma in USA (Parenteral)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top